Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Call Transcript

But what you do see for the rest of this year, there’s a number of other extremely important potential medicines in our pipeline. I’m not sure that there’s any company out there that has the number of Phase II and Phase III trial readouts coming in the next 6 months as we do. And if you extend it out into the first half of next year, it nearly doubles. So there’s a tremendous amount of information that we’re going to be generating in just the next few months, and we very much look forward to talking to you about all these. This company is actually hitting on all cylinders right now. We’re always looking for a way to improve, and we continue to look for ways to improve our business, but I couldn’t be more happy with the way the company is running at this point.

So with that, I’ll sign off and look forward to talking to all of you in the near future.

Operator: This does conclude today’s program. Thank you for your participation. You may disconnect at any time, and have a wonderful day.